An FDA warning letter lays out failures by a Torrent Pharmaceuticals plant that figures into the global recall of tainted high blood pressure meds.

Pfizer's role as the hero in ramping up production of a chemo drug badly needed by pediatric oncologists is a turnabout for the drugmaker.

Lupin has named a new global head of quality even as another of its plants gets an FDA Form 483.

Chinese drugmaker BeiGene has opened the first phase of a $320 million facility where it intends to manufacture targeted cancer drugs.

India’s Aurobindo, which has been racking up FDA actions right and left, acknowledged Monday a recent agency inspection resulted in a Form 483. 

Johnson & Johnson has expanded its Cork Co., Ireland biologics site with a $350 million facility, adding 200 jobs in the process.

After some recalls of defective creams, India's Glenmark has received a warning letter for the plant where they were manufactured.

French CDMO Delpharm is planning a big expansion with a $274 million deal to pick up five sites from financially struggling Famar.